Mardhiah M, Azize Nor Azimah Abdul, Yakob Yusnita, Affandi O, Hock Ngu Lock, Rowani M R, Habib Anasufiza
Biochemistry Unit, Specialised Diagnostic Centre, Institute for Medical Research, Kuala Lumpur, Malaysia.
Molecular Diagnostic Unit, Specialised Diagnostic Centre, Institute for Medical Research, Kuala Lumpur, Malaysia.
Mol Genet Metab Rep. 2019 Dec 19;22:100548. doi: 10.1016/j.ymgmr.2019.100548. eCollection 2020 Mar.
Biotinidase deficiency (BD) is an autosomal recessively inherited disorder characterized by developmental delay, seizures, hypotonia, ataxia, skin rash/eczema, alopecia, conjunctivitis/visual problem/optic atrophy and metabolic acidosis. Delayed diagnosis may lead to irreversible neurological damage.
Clinically suspected patients were screened for biotinidase level by a fluorometry method. Profound BD patients were confirmed by mutation analysis of gene.
9 patients had biotinidase activity of less than 77 U. 3 patients (33%) had profound BD while 6 patients (67%) had partial BD. Compound heterozygous mutations were detected at c.98_104delinsTCC p.(Cys33Phefs36) in Exon 2 and c.833T>C p.(Leu278Pro) in Exon 4 in two patients and a homozygous mutation at c.98_104delinsTCC p.(Cys33Phefs36) in Exon 2 in another patient.
Correct diagnosis lead to early treatment and accurate management of patient. Biochemical screening of BD in symptomatic child is prerequisite to determine enzyme status however molecular confirmation is vital in differentiating individuals with profound biotinidase deficiency from partial biotinidase deficiency and also individuals' carriers.
生物素酶缺乏症(BD)是一种常染色体隐性遗传疾病,其特征为发育迟缓、癫痫发作、肌张力减退、共济失调、皮疹/湿疹、脱发、结膜炎/视力问题/视神经萎缩以及代谢性酸中毒。诊断延迟可能导致不可逆的神经损伤。
对临床疑似患者采用荧光测定法筛查生物素酶水平。通过基因的突变分析确诊重度BD患者。
9例患者的生物素酶活性低于77 U。3例患者(33%)为重度BD,6例患者(67%)为部分BD。在两名患者的外显子2中检测到c.98_104delinsTCC p.(Cys33Phefs36)和外显子4中c.833T>C p.(Leu278Pro)的复合杂合突变,另一名患者在外显子2中检测到c.98_104delinsTCC p.(Cys33Phefs36)的纯合突变。
正确诊断有助于患者的早期治疗和精准管理。对有症状儿童进行BD的生化筛查是确定酶状态的前提条件,然而分子确诊对于区分重度生物素酶缺乏症患者与部分生物素酶缺乏症患者以及个体携带者至关重要。